查詢結果分析
相關文獻
- Puerperal Lactation Suppression by Metergoline Versus Bromocriptine
- Olanzapine治療後病患受孕:一例報告
- 精神分裂症病患之高泌乳激素血症
- 淺談中醫對泌乳激素偏高的治療
- Hyperprolactinemia in Systemic Lupus Erythematosus
- Characterization of Pulsatile Secretion of Gonadotropin and Prolactin in Women with Normalmenstrual Cycle,Secondary Amenorrhea and Polycystic Ovary Syndrome(Pcos)
- 疏肝解鬱治高泌乳激素血症
- Bromocriptine Treatment of Postoperative Prolactinoma Patients
- Computed Tomography of the Brain in Patients With Serum Prolaction Levels Over 200ng/ml
- The Use of Thyrotropin-Releasing Hormone in Distinguishing Prolactinoma and Successful Outcome of Bromocryptine-Induced Pregnancies in 7 Women with Prolactinoma
頁籤選單縮合
題 名 | Puerperal Lactation Suppression by Metergoline Versus Bromocriptine=Metergoline與Bromocriptine在產後泌乳之抑制 |
---|---|
作 者 | 林鶴雄; 許博欽; 蘇怡寧; 魏凌鴻; 黃思誠; | 書刊名 | 中華民國婦產科醫學會會刊雜誌 |
卷 期 | 36:3 1997.09[民86.09] |
頁 次 | 頁91-95 |
分類號 | 417.38 |
關鍵詞 | 產後乳汁分泌; 泌乳激素; Puerperal lactation; Prolactin; Metergoline; Bromocriptine; |
語 文 | 英文(English) |
中文摘要 | 目的:比較metergoline與bromocriptine在產後泌乳抑制之效果。 方法:此為前瞻性的隨機臨床試驗。共收集83位產婦並隨機地分成四組-A1組為自然生 產(24例)和A2組剖腹產(18例),此二組均服用metergoline;另外有23位自然生產例(B1 組)及18位剖腹產例(B2)組為使用bromocriptine。藥物之使用,在自然生產例,產後12小 時內服用,而在剖腹產例則在產後36小時內開始。在服藥及停藥後,評估臨床症狀:包括乳 汁分泌之抑制狀態、胸脹、胸痛以及是否存在任何副作用。在服藥前及服藥3日後(即出院時) 收集每例配對的血清,測量其泌乳激素濃度,以求出每一位產婦之泌乳激素受到抑制之比率。 結果:四組產婦中其平均年齡、生產數和服藥前泌乳激素之濃度並無統計學上之差異。 不過在服用bromocriptine組比metergoline組對泌乳激素抑制之比率較佳(89%對83%, P<0.05)。但是,每一位產婦其乳汁分泌抑制之臨床評估均十分良好,而且在追蹤期間並無任 何明顯副作用。 結論:此二種藥物在抑制產後乳汁分泌的作用均相當有效。 |
英文摘要 | Objective: To compare the efficacy of puerperal lactation suppression by metergoline versus bromocriptine. Methods: A prospective, randomized clinical trial of patients with puerperal lactation suppression. Eighty-three parturients were recruited and randomly divided into 4 groups. Group Al consisted of 24 normal spontaneous delivery cases treated by metergoline and group A2 was 18 cesarean delivery cases treated by metergoline. Another 23 normal spontaneous delivery cases (group B1) and 18 cesarean delivery cases (group B2) were treated by bromocriptine. The clinical assessment during and after medication included the status of inhibition of breast milk secretion, breast engorgement and pain as well as the presence of side-effects. In addition, paired serum samples of prolactin levels before medication and the third day after medication (the day of discharge) were measured and the suppression rate of the prolactin level in each case was determined. Results: The mean age, parity and pre-treatment prolactin level were not statistically significant among the four groups. In contrast, the suppression rate of the prolactin level by bromocriptine was statistically greater than that by metergoline (89% vs. 83%, p<0.05). However, the clinical assessment of lactation inhibition was excellent in each case, and no patients showed any obvious side-effects during follow-up. Conclusions: Both drugs were effective in puerperal lactation suppression and clinical assessment of their lactation inhibition was good. |
本系統中英文摘要資訊取自各篇刊載內容。